<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369694</url>
  </required_header>
  <id_info>
    <org_study_id>446-Med/ERC-05</org_study_id>
    <nct_id>NCT00369694</nct_id>
  </id_info>
  <brief_title>Short Course Terlipressin for Control of Acute Variceal Bleeding</brief_title>
  <official_title>Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aga Khan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferozsons Laboratories Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aga Khan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 24 hours of Terlipressin is as effective as
      72 hours of Terlipressin in preventing re-bleed once esophageal variceal bleed has been
      controlled with endoscopic therapy (variceal band ligation or sclerotherapy) in low to
      moderate risk variceal bleed patients and hence can save cost and may decrease length of
      hospital stay especially in the I.C.U or high dependency units.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The esophageal variceal bleeding is usually controlled with endoscopic treatment of variceal
      band ligation or sclerotherapy along with vasoactive drugs like Terlipressin or Octreotide.
      The risk of re-bleeding is highest during the initial 5 days from first presentation.
      Terlipressin is usually given for 3 days (72 hours). In this study we are trying to prove
      that among low to moderate risk patients, a short course of 1 day (24 hours) of Terlipressin
      is as effective as 3 days (72 hours) in preventing re-bleed once bleeding has been controlled
      with endoscopic therapy. This intervention will save 2 days cost incurred on the Terlipressin
      and may also help in decreasing the length of hospital stay in future.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variceal Re-bleed</measure>
    <time_frame>120 hours (5 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause 30 days mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 days rebleed</measure>
    <time_frame>30 days from index bleed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Terlipressin</measure>
    <time_frame>In Hospital safety</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Esophageal Varices</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>72 hours of Terlipressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>24 hours of Terlipressin &amp; then next 48 hours of Dummy of Terlipressin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Novapressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin &amp; then Dummy</intervention_name>
    <description>2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Novapressin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute esophageal variceal bleed

          -  Liver cirrhosis

          -  Child's score &lt;/= 11

        Exclusion Criteria:

          -  Patient on Mechanical ventilator and or ionotropic support

          -  Active angina, Recent Myocardial infarction or dynamic EKG changes

          -  Failure to control variceal bleed on initial endoscopy

          -  Gastric variceal bleed

          -  Spontaneous bacterial peritonitis at presentation

          -  Hepatocellular carcinoma or other liver metastatic malignancy

          -  Portal vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saeed S Hamid, FRCP, FACG</last_name>
    <role>Study Chair</role>
    <affiliation>The Aga Khan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zahid SM Azam, MBBS, FCPS</last_name>
    <role>Study Director</role>
    <affiliation>The Aga Khan University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wasim SM Jafri, FRCP, FACG</last_name>
    <role>Study Director</role>
    <affiliation>The Aga Khan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Aga Khan University Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Ethical Review Committee (ERC)</name_title>
    <organization>The Aga Khan University</organization>
  </responsible_party>
  <keyword>Esophageal varices</keyword>
  <keyword>Portal Hypertension</keyword>
  <keyword>Melena</keyword>
  <keyword>Hematemesis</keyword>
  <keyword>Gastrointestinal Hemorrhage</keyword>
  <keyword>Terlipressin</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

